Karyopharm Therapeutics Inc.
NASDAQ:KPTIBiotechnology
-$0.34 today
- Market cap
- $158.87M
- Beta
- 0.82
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$8.86
Volume 0.67M
Average 0.85M
Financial health
Karyopharm Therapeutics Inc. financial health
Start with the overall verdict and the rule-based risk checks for KPTI, then work through liquidity, debt, balance-sheet quality, and claims on cash.
Financial health snapshot
Leverage or liquidity signals may be adding financial risk.
Cash & Investments
$91.17M
Debt Cushion
-$139.71M
Current Ratio
1.1x
Interest Coverage
Not available
Risk checks
7 of 9 checks flagged
Positive equity
Negative
Passes when: Shareholders’ equity is above zero.
Interest coverage
-1.8×
Passes when: Operating income is at least 1.5 times interest expense.
Manageable net debt
Negative EBITDA
Passes when: Net debt is below 3 times EBITDA.
Debt repayment from cash flow
Negative FCF
Passes when: Free cash flow could repay all debt within 5 years.
Altman Z-score trend
-14.22 → -23.89
Passes when: The Z-score is stable or rising, or stays above 2.99.
Debt growth versus revenue growth
9.3% vs. -2.4%
Passes when: Over three years, debt growth is no more than 5 percentage points above revenue growth.
Share dilution
+17.9% per year
Passes when: Diluted share count grows no more than 2% per year.
Short-term liquidity
1.1×
Passes when: Current assets are at least 1 times current liabilities.
Near-term debt coverage
2.8×
Passes when: Cash and short-term investments cover debt due within 12 months.
Financial strength scores
How strong are the fundamentals over time?
Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.
Financial strength scores
Piotroski F-Score and Altman Z-Score from the latest reported financials
No financial scores available.
Score history
Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.
| Score | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Piotroski F (0–9) | 2 | 4 | 5 | 3 | 4 | 4 | 3 | 2 | 2 | 3 |
| Altman Z | 7.55 | -0.37 | -1.38 | -2.28 | -2.87 | -4.23 | -4.73 | -8.85 | -14.22 | -23.89 |
Piotroski: 8–9 strong, 4–7 average, 0–3 weak. Altman: above 2.99 safe, 1.81–2.99 grey, below 1.81 distress. Our calculation can differ slightly from the provider's current scores above.
Liquidity
Can it meet short-term obligations?
Check whether cash and current assets cover what falls due within a year without depending on fresh financing.
Cash & Equivalents
$90.85M
Q1 2026
Quick Ratio
1.0x
Q1 2026
Current Ratio
1.1x
Q1 2026
Cash Ratio
0.8x
Q1 2026
Working capital
How quickly does cash come back?
Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.
Working capital and cash conversion
Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.
Working capital (Q1 2026)
$9.03M
Current assets − current liabilities
Days sales outstanding
65 d
-12 days vs. prior year
Days inventory outstanding
248 d
-40 days vs. prior year
Days payables outstanding
246 d
-65 days vs. prior year
Cash conversion cycle
68 d
+13 days vs. prior year
Leverage
How much debt risk sits on the balance sheet?
Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.
Total Debt
$230.87M
Q1 2026
Debt/Equity
-0.9x
Q1 2026
Debt/Assets
1.8x
Q1 2026
Interest Coverage
—
Q1 2026
Debt service
Can cash flow carry the debt?
Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.
Debt service capacity
Can operating cash flow carry the debt, and how much is due soon?
Net debt
$140.02M
Total debt − cash − short-term investments
Net debt / EBITDA
Negative EBITDA
Above 3× is elevated
Free cash flow / debt
-25.6%
Share of debt one year of FCF could repay
Years to repay debt
Negative FCF
Total debt ÷ free cash flow
Operating cash flow / current liabilities
-0.5×
Above 1× funds a year of obligations
Interest coverage
-1.8×
Operating income ÷ interest expense
Debt maturity
Cash and short-term investments cover short-term debt 2.8×.
Balance sheet as of Q1 2026; cash flows TTM to Q1 2026.
Debt and cash over time
Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.
Balance sheet cushion
How much room is there if conditions weaken?
Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.
Long-Term Investments
$317,000.00
Q1 2026
Assets
$131.42M
Q1 2026
Liabilities
$397.06M
Q1 2026
Balance sheet quality
Who funds the assets, and how tangible is the equity?
Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.
Balance sheet quality
Who funds the assets, and how much of the equity is tangible (Q1 2026).
$397.06M in liabilities against $131.42M in assets
- Payables1.1%
- Short-term debt8.1%
- Long-term debt48.4%
- Deferred revenue18.2%
- Other liabilities24.2%
Shareholders' equity is negative (-$265.65M), so liabilities exceed total assets. Buybacks funded with debt are a common cause; check whether cash flow supports the debt.
Goodwill + intangibles
$0
0.0% of total assets
Share of equity
Negative equity
Above 50% leaves little tangible backing
Tangible equity
-$265.65M
Equity left after writing off goodwill and intangibles
Deferred revenue
$72.34M
Customer prepayments: a liability settled by delivering service, not cash
Competitor health
How does Karyopharm Therapeutics Inc. compare with peers?
Compare leverage, interest coverage, and liquidity ratios with similar companies.
Competitor Health
Peer financial health comparison
| Company | Market Cap | D/E | D/Assets | ND/EBITDA | Int. Cov. | Quick | Current | Cash |
|---|---|---|---|---|---|---|---|---|
X4 Pharmaceuticals, Inc. XFOR:NASDAQ | $360.30M | 0.41 | 0.27 | 2.03 | — | 9.98 | 10.16 | 8.43 |
INmune Bio, Inc. INMB:NASDAQ | $50.51M | 0.04 | 0.03 | 0.52 | — | 3.55 | 3.55 | 2.94 |
Telomir Pharmaceuticals, Inc. Common Stock TELO:NASDAQ | $38.16M | 0.08 | 0.06 | 0.65 | — | 5.14 | 5.14 | 5.10 |
Questions
Financial health questions
Common questions about KPTI's balance sheet, answered from the reported figures.
Is KPTI's balance sheet healthy?
Karyopharm Therapeutics Inc. (KPTI) has a current ratio of 1.08, a quick read on short-term liquidity.
How leveraged is KPTI?
Debt to equity is -0.87, which helps judge how much financing risk sits on the balance sheet.
Continue the stock analysis
Jump to another research area for this company.